Stockreport

Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference [...

Ardelyx, Inc.  (ARDX) 
Last ardelyx, inc. earnings: 3/6 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ardelyx.com/investor-relations
PDF and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA ® (tenapanor) w [Read more]